Physician profile

Robert C Hill

Family Medicine · Salt Lake City, UT

NPI 1770521643

$1,613.38

in general payments reported to CMS, 2019-2025

31 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals Lp $154.56 2019-2021
Boehringer Ingelheim Pharmaceuticals, INC. $153.50 2019-2020
Sanofi-Aventis U.S. LLC $128.29 2019-2020
Pfizer INC. $114.73 2019-2020
Novo Nordisk INC $112.87 2019-2021
Amarin Pharma, INC. $106.41 2019-2021
Amgen INC. $97.81 2019-2021
Takeda Pharmaceuticals U.S.A., INC. $87.64 2019-2021
Merck Sharp & Dohme LLC $77.71 2019-2021
Boston Scientific Corporation $74.29 2019-2021
Abbvie INC. $41.89 2020-2021
Lilly USA, LLC $40.33 2019-2021
Regeneron Healthcare Solutions, INC. $40.13 2019
Gilead Sciences, INC. $39.76 2019-2020
Allergan, INC. $34.57 2020
Show all 31 companies

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert C Hill

$1,613.38

in general payments reported 2019-2025

Years
2019-2021
Top company
Astrazeneca Pharmaceuticals Lp

https://glasscript.com/doctor/555802/robert-c-hill

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.